OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp.) and OSR Holdings Co., Ltd. have successfully completed their business combination, marking a significant milestone in the global healthcare industry. The combined entity, now operating as OSR Holdings, Inc., is set to drive growth and innovation in the sector. Here's a closer look at the implications of this strategic move.

The completion of the business combination between OSR Holdings, Inc. and OSR Holdings Co., Ltd. is expected to have a positive impact on the valuation and growth prospects of the combined entity. Here's how:

1. Access to a Diverse Portfolio of Innovative Therapies and Healthcare Solutions: OSR Holdings Co., Ltd. has a robust portfolio of innovative and potentially transformative therapies and healthcare solutions, including oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical devices. This diverse portfolio can drive growth and enhance the valuation of the combined entity.
2. Global Presence and Expansion Opportunities: OSR Holdings Co., Ltd. operates in the US, Europe, and South Korea, providing a strong global footprint. This global presence can open up new markets and expansion opportunities, further driving growth and increasing the valuation of the combined entity.
3. Strategic Acquisitions and Partnerships: OSR Holdings Co., Ltd. has a vision to acquire and operate a portfolio of innovative healthcare-related companies globally. This strategic approach can lead to further growth and increased valuation through successful acquisitions and partnerships.
4. Institutional Support and Investor Confidence: The successful completion of the business combination, particularly in the current market environment where many SPAC deals face challenges, suggests strong institutional support and investor confidence in the merger's strategic rationale. This confidence can translate into higher valuation for the combined entity.

The successful completion of the business combination indicates that all necessary shareholder approvals, regulatory requirements, and closing conditions have been met. This transition from Bellevue Life Sciences Acquisition Corp. (BLAC) to OSR Holdings signifies the merger's effectiveness and the beginning of the combined company's journey as a publicly traded entity. The seamless execution of this business combination, particularly in the current market environment where many SPAC deals face challenges, suggests strong institutional support and investor confidence in the merger's strategic rationale.

OSR Holdings, Inc. is now set to begin trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025, under the ticker symbols "OSRH" and "OSRHW" for common stock and warrants, respectively. With a strong global presence, a diverse portfolio of innovative therapies, and a strategic approach to acquisitions and partnerships, OSR Holdings, Inc. is well-positioned to drive growth and create long-term value for its shareholders, subsidiary founders, and investors.